TrialThe Lancet. Oncology2016

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

David Cella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.